Recently, Jiudian Hongyang passed the on-site verification of the registration of API lacidipine and the GMP compliance inspection of 5 varieties including oseltamivir phosphate.

From October 22 to November 8, Jiudian Hongyang welcomed the on-site verification of the registration of API lacidipine, the GMP compliance inspection of API, and the on-site inspection of the change of the "Drug Production License" of the production workshop for the combined change of oseltamivir phosphate, involving 6 APIs varieties including lacidipine, oseltamivir phosphate, tadalafil, tolterodine tartrate, lidocaine, and potassium sulfate. This three-cycle on-site inspection involved a total of 4 production workshops. 

During the on-site inspection, the provincial bureau inspectors conducted a comprehensive inspection of the company's production management, quality management, material management, and plant facilities and equipment management. The inspectors fully affirmed our production quality management and expressed the hope that Hongyang would continue to strictly control production quality.

The on-site inspection of the registration of the API lacidipine and the on-site inspection of the GMP compliance of 5 API varieties such as oseltamivir phosphate were successfully passed, which not only enriched the number of varieties of the company's API registration and approval for marketing, but also had great significance for the company's steady development and the production and sales of API varieties. In the future, the company will learn from the valuable improvement suggestions put forward by the inspectors, continuously improve the production and quality management system, and contribute to the sustainable and healthy development of the pharmaceutical industry.